XTANDI (enzalutamide), androgen receptor signalling pathway inhibitor

Minor improvement in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer, without indication for chemotherapy

• XTANDI now has Marketing Authorisation in the treatment of metastatic castration-resistant prostate cancer in asymptomatic or mildly symptomatic patients (most intense pain score experienced during the previous 24 hours ≤ 3 on a scale from 0 to 10), after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.
• It improves radiological progression-free survival, overall survival and median time to initiation of cytotoxic chemotherapy.
• XTANDI offers a minor improvement, the same as that of ZYTIGA in the treatment of metastatic castration-resistant prostate cancer prior to treatment with docetaxel.

-